肥胖患者肌松残余的临床研究进展  

Clinical progress of residual neuromuscular block in obese patients

作　　者：罗琪琛 李雅兰[1] Luo Qichen;Li Yalan(Anesthesiology Department,the First Affiliated Hospital of Ji'nan University,Guangzhou 510630,China)

机构地区：[1]暨南大学附属第一医院麻醉科,广州510630

出　　处：《中华肥胖与代谢病电子杂志》2022年第1期61-65,共5页Chinese Journal Of Obesity and Metabolic Diseases：Electronic Edition

摘　　要：肥胖患者的围术期管理一直是麻醉医师关注的热点,而肌松残余与围术期多种不良事件的发生相关联,降低肌松残余发生率将能有效地提高肥胖患者术后康复质量、减少围术期并发症的发生,本文通过肌松残余的评估方法及标准、肥胖患者呼吸系统的病理生理改变、影响肥胖患者肌松残余发生率的相关因素、如何预防肥胖患者发生肌松残余等几个方面来综述目前关于肥胖患者肌松残余的临床研究进展。The perioperative management of obese patients has always been the focus of anesthesiologists,and residual neuromuscular block is associated with a variety of adverse events,reducing the incidence of residual neuromuscular block will effectively improve the quality of postoperative rehabilitation and reduce the incidence of perioperative complications in obese patients.This paper will introduce the current clinical research progress of residual neuromuscular block in obese patients from the aspects of evaluation methods and standards of residual neuromuscular block,pathophysiological changes of respiratory system in obese patients,relevant factors affecting the incidence of residual neuromuscular block in obese patients,and how to prevent residual neuromuscular block in obese patients.

关 键 词：肌松残余 肥胖 非去极化肌松剂 舒更葡糖钠 围术期管理 

分 类 号：R589.2[医药卫生—内分泌]